Kineta (KA) Price Target Increased by 25.58% to 13.77
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 18 2024
0mins
Source: NASDAQ.COM
- Price Target Revision: The average one-year price target for Kineta (NasdaqCM:KA) has been revised to $13.77 per share, showing a 25.58% increase from the prior estimate.
- Fund Sentiment: There are 37 funds or institutions reporting positions in Kineta, with an average portfolio weight decrease of 9.35% and total shares owned by institutions increasing by 5.40% in the last three months.
- Other Shareholders Activity:
- Armistice Capital decreased its ownership of Kineta by 12.62% and reduced its portfolio allocation by 15.50% over the last quarter.
- VTSMX increased its ownership by 47.97% and portfolio allocation by 78.80% in the last quarter.
- VEXMX and Geode Capital Management maintained their ownership percentages, while Northern Trust holds 0.34% ownership of the company.
- Kineta Background Information: Yumanity Therapeutics is a biopharmaceutical company focused on neurodegenerative diseases, with a pipeline including programs for Parkinson's disease, Lewy body dementia, ALS, and Alzheimer's disease.
- Fintel Platform: Fintel is an investing research platform providing comprehensive data on fundamentals, analyst reports, ownership data, fund sentiment, and more, offering exclusive stock picks powered by quantitative models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
